These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy. Schwartz M; Likhite S; Meyer K Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905 [TBL] [Abstract][Full Text] [Related]
3. Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy. Lin PJ; Yeh WS; Neumann PJ Pediatr Neurol; 2017 Jan; 66():69-75. PubMed ID: 27769729 [TBL] [Abstract][Full Text] [Related]
4. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy. McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095 [TBL] [Abstract][Full Text] [Related]
5. Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience. Tokatly Latzer I; Sagi L; Lavi R; Aharoni S; Bistritzer J; Noyman I; Ginsburg M; Lev-Or A; Katzenellenbogen S; Nevo Y; Fattal-Valevski A Pediatr Neurol; 2023 Jul; 144():60-68. PubMed ID: 37149951 [TBL] [Abstract][Full Text] [Related]
6. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Lee BH; Waldrop MA; Connolly AM; Ciafaloni E Muscle Nerve; 2021 Aug; 64(2):153-155. PubMed ID: 33959970 [TBL] [Abstract][Full Text] [Related]
12. Parent Perceptions in Choosing Treatment for Infants With Spinal Muscular Atrophy Diagnosed Through Newborn Screening. Deng S; Lee BH; Ciafaloni E J Child Neurol; 2022 Jan; 37(1):43-49. PubMed ID: 34753336 [TBL] [Abstract][Full Text] [Related]
13. Evolving approaches to prenatal genetic counseling for Spinal Muscular Atrophy in the new treatment era. Zettler B; Estrella E; Liaquat K; Lichten L J Genet Couns; 2022 Jun; 31(3):803-814. PubMed ID: 35037741 [TBL] [Abstract][Full Text] [Related]
15. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Dangouloff T; Vrščaj E; Servais L; Osredkar D; Neuromuscul Disord; 2021 Jun; 31(6):574-582. PubMed ID: 33985857 [TBL] [Abstract][Full Text] [Related]
16. Newborn genetic screening for spinal muscular atrophy in the UK: The views of the general population. Boardman FK; Sadler C; Young PJ Mol Genet Genomic Med; 2018 Jan; 6(1):99-108. PubMed ID: 29169204 [TBL] [Abstract][Full Text] [Related]
17. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190 [TBL] [Abstract][Full Text] [Related]
18. Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma). Ogbonmide T; Rathore R; Rangrej SB; Hutchinson S; Lewis M; Ojilere S; Carvalho V; Kelly I Cureus; 2023 Mar; 15(3):e36197. PubMed ID: 37065340 [TBL] [Abstract][Full Text] [Related]
19. Progress in spinal muscular atrophy research. Wurster C; Petri S Curr Opin Neurol; 2022 Oct; 35(5):693-698. PubMed ID: 35942665 [TBL] [Abstract][Full Text] [Related]
20. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]